CC
Caxton Corporation Portfolio holdings
AUM
$9.85M
This Quarter Return
+40.6%
1 Year Return
+26.35%
3 Year Return
+409.06%
5 Year Return
+527.59%
10 Year Return
+11,054.45%
AUM
$9.85M
AUM Growth
+$9.85M
(+94%)
Cap. Flow
+$2.67M
Cap. Flow
% of AUM
27.11%
Top 10 Holdings %
Top 10 Hldgs %
99.88%
Holding
13
New
1
Increased
3
Reduced
1
Closed
2
Top Buys
| 1 |
Rezolute
RZLT
|
$1.27M |
| 2 |
SPDR Gold Trust
GLD
|
$1.11M |
| 3 |
Enliven Therapeutics
ELVN
|
$263K |
| 4 |
Berkshire Hathaway Class B
BRK.B
|
$80.2K |
Top Sells
| 1 |
Cardiff Oncology
CRDF
|
$41.7K |
| 2 |
Adicet Bio
ACET
|
$13.2K |
| 3 |
Lexeo Therapeutics
LXEO
|
$2.09K |
Sector Composition
| 1 | Healthcare | 81.56% |
| 2 | Financials | 3.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Rezolute
RZLT
$619M
| $7.15M | 72.6% | 1,603,986 +285,019 | +22% | +$1.27M |
|
|
2
SPDR Gold Trust
GLD
$107B
| $1.51M | 15.32% | 4,952 +3,654 | +282% | +$1.11M |
|
|
3
Berkshire Hathaway Class B
BRK.B
$1.09T
| $307K | 3.12% | 632 +165 | +35% | +$80.2K |
|
|
4
Enliven Therapeutics
ELVN
$1.2B
| $263K | 2.67% | +13,097 | New | +$263K |
|
5
MindMed
MNMD
$676M
| $221K | 2.24% | 34,073 | – | – |
|
6
Compass Therapeutics
CMPX
$483M
| $113K | 1.15% | 43,465 | – | – |
|
|
BCAX
7
Bicara Therapeutics Inc. Common Stock
BCAX
$651M
| $102K | 1.03% | 10,941 | – | – |
|
8
Kyverna Therapeutics
KYTX
$160M
| $70.6K | 0.72% | 22,981 | – | – |
|
|
9
Lexeo Therapeutics
LXEO
$259M
| $69.7K | 0.71% | 17,332 -519 | -3% | -$2.09K |
|
10
Inhibikase Therapeutics
IKT
$134M
| $32K | 0.32% | 16,393 | – | – |
|
11
Context Therapeutics
CNTX
$75.4M
| $12.1K | 0.12% | 18,403 | – | – |
|
|
12
Adicet Bio
ACET
$59.9M
| – | – | -17,488 | Closed | -$13.2K |
|
|
13
Cardiff Oncology
CRDF
$140M
| – | – | -13,287 | Closed | -$41.7K |
|